Maxformin 750 Tablet PR contains Metformin 750 mg, an oral antihyperglycemic agent belonging to the biguanide class, primarily indicated for the management of type 2 diabetes mellitus. It functions by improving glucose tolerance through decreasing hepatic glucose production, decreasing intestinal absorption of glucose, and enhancing insulin sensitivity by increasing peripheral glucose uptake and utilization. Maxformin 750 Tablet PR is formulated as a prolonged-release tablet to provide a sustained therapeutic effect, thereby improving patient compliance by reducing dosing frequency. It is prescribed as an adjunct to diet and exercise to achieve better glycemic control in patients inadequately controlled on diet alone or in combination with other antidiabetic agents. The medication is contraindicated in patients with renal impairment, metabolic acidosis, or hypersensitivity to Metformin. Common adverse effects include gastrointestinal disturbances such as nausea, vomiting, diarrhea, and abdominal discomfort, which often subside with continued use. Rare but serious adverse effects include lactic acidosis, necessitating prompt medical attention. Dosage adjustments may be required based on renal function and clinical response. Regular monitoring of blood glucose levels, renal function, and vitamin B12 status is recommended during therapy with Maxformin 750 Tablet PR to ensure safety and efficacy.